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ABSTRACT
Nuclear factor TDP-43 has been reported to play
multiple roles in transcription, pre-mRNA splicing,
mRNA stability and mRNA transport. From a struc-
tural point of view, TDP-43 is a member of the
hnRNP protein family whose structure includes
two RRM domains flanked by the N-terminus and
C-terminal regions. Like many members of this
family, the C-terminal region can interact with cellu-
lar factors and thus serve to modulate its function.
Previously, we have described that TDP-43 binds to
several members of the hnRNP A/B family through
this region. In this work, we set up a coupled mini-
gene/siRNA cellular system that allows us to obtain
in vivo data to address the functional significance of
TDP-43-recruited hnRNP complex formation. Using
this method, we have finely mapped the interaction
between TDP-43 and the hnRNP A2 protein to the
region comprised between amino acid residues 321
and 366. Our results provide novel details of protein–
protein interactions in splicing regulation. In addi-
tion, we provide further insight on TDP-43 functional
properties, particularly the lack of effects, as seen
with our assays, of the disease-associated muta-
tions that fall within the TDP-43 321-366 region:
Q331K, M337V and G348C.
INTRODUCTION
Nuclear factor TDP-43 is a multifunctional RNA binding
protein that has been described to play a role in transcrip-
tion, pre-mRNA splicing, mRNA stability and mRNA
transport (1–4). Recently, it has also been described to
participate in pathological processes such as cystic ﬁbrosis
(5) and a series of neurodegenerative diseases that include
Fronto Temporal Lobar Degeneration (FTLD-U) and
Amyotrophic Lateral Sclerosis (ALS) (6,7), as reviewed
in several publications (8–12). For these reasons, the
detailed characterization of the properties of this protein
may well be crucial for future diagnostic, prognostic and
therapeutic applications. TDP-43 is a member of the
hnRNP protein family (13) that comprises several proteins
with numerous functions (14,15) including some of
the best well-known splicing modulators, such as PTB
(hnRNP I), hnRNP A/B and hnRNP H (16).
Structurally, the TDP-43 protein is divided in four well-
deﬁned regions, an N-terminal sequence that contains a
Nuclear Localization Signal (17), two RNA Recognition
Motifs of which only the ﬁrst has been described to be
involved in RNA binding (18) and a Gly-rich C-terminal
region that in other hnRNPs normally mediates protein–
protein interactions. Consistent with a role of the
C-terminal tail in TDP-43 activity, we have previously
demonstrated that this region is essential for TDP-43 to
function as splicing silencer in the CFTR exon 9 and Apo
AII exon 3 systems (19,20). We proposed that inhibition
of splicing by TDP-43 depends on the interaction of the
C-tail with members of the hnRNP A/B family and espe-
cially hnRNP A2, as determined by pull-down analysis
(20). Interestingly, the C-terminal region is also required
for the ability of TDP-43 to act as a transcriptional insu-
lator for the mouse SP-10 gene, as reported by Abhyankar
et al. (21). Taken together, the functional evidence gath-
ered so far has identiﬁed the C-terminal region of TDP-43
as a crucial domain governing the protein’s functional
properties. The importance of the C-terminus has also
been highlighted by the observation that  2–3% of
patients aﬀected by sporadic and familial forms of ALS
carry speciﬁc missense mutations in the C-terminus of
TDP-43 (22–29), as recently reviewed by Banks et al.
(30). Presently, there is no information with regards to
which activity of the protein may be aﬀected by these
mutations although some have been associated with neu-
rotoxicity (22) or increased degradation (23). From a
molecular point of view, a likely possibility is that they
may interfere with some essential protein–protein interac-
tions such as the association with hnRNP A/B proteins.
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dies regarding the interaction of TDP-43 with hnRNP
proteins by setting up an in vivo functional system that
couples siRNA knock-down of endogenous TDP-43 and
add-back of siRNA resistant proteins in HeLa cells. We
have been able to ﬁnely map the region of interaction
between TDP-43 and hnRNP proteins and to assess the
importance of disease-related missense mutations in this
region. Finally, we show that the hnRNP binding proper-
ties are evolutionarily conserved among TDP-43 orthologs
even in conditions of limited sequence homology.
MATERIALS AND METHODS
Plasmid preparation
All GST tagged TDP-43 mutants were generated using as
template the pGEX3X-TDP-43 (5) plasmid using primers
TDP BamFW (50-ggggatcctctgaatatattcgggtaac-30), and
TDP315EcoREV (50-gggaattctcacgcaccaaagttcatcccaccac
c-30) or TDP 366EcoREV (50-gggaattcggcctggtttggctccctc
tg-30) and cloned in pGEX3X between BamHI and EcoRI.
The deletion mutants were generated with primers TDP
BamFW, TDPEcoREV (50-gggaattctcacattccccagccagaa
gac-30), TDPdelta321-366FW (50-gcgttcagcattaatccattcggt
tctggaaataac-30) andTDPdelta321-366REV (50-gttatttccag
aaccgaatggattaatgctgaacgc-30) whilst the Q331K, M337V
and G348C carrying TDP-43 sequences were ampliﬁed
with suitable primers carrying each point mutation
(sequence available upon request). The GST-tagged
TBPH, TBPH C, have already been described by
Ayala et al. (19) whilst GST-tagged hnRNP A2 proteins
has been described in Buratti et al. (20).
The FLAG-tagged mutants generation has already been
described by Ayala et al. (31) apart from the pFLAG
321-366 mutant that was ampliﬁed from pGEX3X
321-366 with primers TDPHindFW (50-cccaagctttctgaat
atattcgggtaaccg-30) and TDPKpnREV (50-ggggtacctcacatt
ccccagccagaagac-30). The FLAG-tagged TBPH was ampli-
ﬁed from pGEX TBPH with primers DROHindFW (50-cc
caagcttgatttcgttcaagtgtcgga-30) and DROKpnREV (50-ggg
gtaccaagaaagtttgacttctccg-30). The FLAG-tagged TDP-43
mutants Q331K, M337V and G348C were ampliﬁed from
the relative pGEX3X vectors with the primers
TDPHindFW and TDPKpnREV. All the pFLAG TDP
mutants were cloned HindIII/KpnI in pFLAG-CMV2. In
addition, a silent mutation was introduced in all the
pFLAG TDP-43 mutants using standard PCR procedure
in order to make them resistant to the anti-TDP-43
siRNA. Primers were the following: siTDP_KOFW (50-t
aattctaagcagtcccaggatga-30) and siTDP_KOREV (50-tcatc
ctgggactgcttagaatta-30).
The reporter minigene used in all splicing assays,
pTB CFTR C155T, has already been described by
Pagani et al. (32).
Peptide synthesis
Peptide 321-366 was synthesized on solid phase (Fmoc/
t-Bu chemistry) using a home-built automatic synthesizer
based on a Gilson Aspec XL SPE system. The peptide-
resin (preloaded NovaSyn TGT, Novabiochem) was
cleaved/deprotected using a modiﬁed Reagent H mixture
(triﬂuoroacetic acid 80%, phenol 3%, thioanisole 3%,
3,6-dioxa-1,8-octanedithiol 8%, water 2.5%, methylethyl-
sulﬁde 2%, hydroiodic acid 1.5% w/w) for 3h. The pep-
tide was then precipitated by diethylether, washed and
freeze dried. The peptide was puriﬁed by preparative
RP-HPLC on a 25 300mm column (Load&Lock
system, Varian) packed with VariTide RPC resin
(Polymer Laboratories—Varian) using a gradient from
0.1% TFA in water to 0.1% TFA in acetonitrile. The
puriﬁed fractions were checked by ESI-MS, pooled and
freeze dried.
Tissue culture and add-back assay
HeLa cell line was grown in DMEM-Glutamax-I
(GIBCO) supplemented with 10% fetal bovine serum
(Euroclone) and Antibiotic–Antimycotic stabilized sus-
pension (Sigma). Cells were grown overnight and trans-
fected with Eﬀectene Transfection reagent (Qiagen)
according to manufacturer’s instructions.
For the add-back experiment, HeLa cells were plated at
30% of conﬂuence (Day 0) and two rounds of TDP-43
siRNA transfections were carried out according to the
procedure already described (33) on Days 1 and 2 in
order to maximize TDP-43 silencing eﬃciency.
Transfection of 0.5mg of the reporter minigene together
with 1mg of pFLAG-expressed proteins was performed on
Day 3. Cells were harvested on Day 4 and total RNA was
collected with Trizol Reagent (Invitrogen). The siRNA
target sequences used to silence the diﬀerent hnRNP pro-
teins are the following: 50-cagctgaggaagctcttca-30 (hnRNP
A1), 50-ggaacagttccgtaagctc-30 (hnRNP A2) and 50-gcaaac
aagcagtagagat-30 (hnRNP C1/C2). Reverse transcription
was performed using M-MLV Reverse Transcriptase
(Invitrogen), according to the manufacturer’s protocol.
PCR with DNA Polymerase (Roche) was carried out for
35 ampliﬁcation cycles (958C for 30s, 558C for 30s and
728C for 30s). PCR products were analyzed on 1.5% agar-
ose gels.
Western blot and GST-overlay/Far Western analyses
Western blotting was performed according to standard
protocols using rabbit polyclonal antibody speciﬁc for
TDP-43 previously described by Buratti et al. (5), a com-
mercially available mouse monoclonal antibody speciﬁc
for the FLAG peptide (Sigma, F1804) and an in-house
made mouse polyclonal antibody for tubulin. The GST-
overlay/Far Western method has been described in detail
elsewhere (20).
Protein expression and EMSA analyses
All pGEX-3X vectors were transformed in BL21-DE3
bacterial cells and recombinant protein expression and
puriﬁcation was performed according to the procedure
already described by Buratti et al. (5). Electro-mobility
shift assays (EMSAs) were conducted according to proce-
dures already described (18) with minor modiﬁcations.
The binding buﬀer contained 10mM NaCl, 10mM
Tris pH 8.0, 2mM MgCl2, 5% glycerol and 1mM DTT.
The RNA oligonucleotide (UG)6 50-uguguguguguga-30
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labeling of the oligonucleotide was carried out with PNK
according to standard protocols. In all experiments,
100 ng of each GST fusion protein and 0.5ng of labeled
oligonucleotide were incubated at room temperature for
10min before loading in a ﬁnal 20ml volume. In super-
shift analysis, 1mg of hnRNP A2 were added to this
mix. Native 5% gels were run at 100–120V at 48C. Gels
were dried before X-OMAT ﬁlm or Cyclone (Packard)
exposure.
RESULTS
Setting up a coupled minigene/siRNA system to assay
TDP-43 splicing inhibitory activity
The aim of our work was to set up a cell-based system to
provide an accurate in vivo testing system to characterize
the structural and functional determinants of TDP-43 spli-
cing activities. This assay was composed of three phases:
RNAi mediated knock-down of endogenous TDP-43 in
HeLa cells as previosuly described (34), add-back of
wild-type (WT) or mutant TDP-43 proteins whose
mRNA sequence was modiﬁed to be resistant to the
siRNA used and ﬁnally the assessment of their splicing
inhibitory activity using minigene analysis. Added-back
TDP-43 proteins were FLAG tagged so the expression
levels could be easily monitored through western blots.
Concerning the minigene, we used a CFTR exon 9 mini-
gene as a substrate (Figure 1A) containing a previously
described disrupting mutation in a splicing regulatory ele-
ment (C155T) (32). TDP-43 inhibition of CFTR exon 9
recognition depends on the presence of a speciﬁc target
sequence composed of UG repeats at the 30 splice site of
the exon. In normal conditions, this resulted in  50% of
exon inclusion when transfected in HeLa cells (Figure 1C,
lane 1). In order to test the performance of the system, we
initially used two add-back plasmids coding for WT TDP-
43 and for its Drosophila homolog (TBPH) previously
shown to possess the same inhibitory eﬀect of human
TDP-43 in an in vitro splicing system (19). As negative
control, we used a TDP-43 mutant that is unable to
bind UG repeats due to the F147L and F149L mutations
(18) in its ﬁrst RRM-1 (Figure 1B). As shown in
Figure 1C, transfection of the CFTR minigene in cells
depleted of endogenous TDP-43 resulted in a substantial
improvement of CFTR exon 9 inclusion (>80%)
(Figure 1C, lane 2). As expected, inclusion levels could
be successfully reduced following the addition of siRNA-
resistant WT TDP-43 and of TBPH (Figure 1C, lanes 3
and 4), but were not aﬀected by expression of the TDP-43
carrying the mutations in RNA binding domain 1
(Figure 1C, lane 5). The western blot against the Flag-
tagged of the diﬀerent proteins shows that all three were
Figure 1. (A) A schematic diagram of the CFTR C155T minigene transfected in our add-back assay (dotted lines represent possible splicing
outcomes). (B) Three schematic diagrams of TDP-43 WT, Drosophila TDP-43 (TBPH) and TDP-MUT proteins. The two crosses in the TDP
MUT diagram represent the F147L/F149L mutations that make this mutant unable to bind UG repeats. (C) The eﬀect on CFTR exon 9 splicing of
adding back these three proteins following knock-down of the endogenous TDP-43. Standard deviations obtained in three independent transfection
experiments are shown. The western blots against the endogenous TDP-43, tubulin and FLAG peptide are shown in the lower boxes to show
silencing eﬃciency, equal loading and proper transgene expression.
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shown in Figure 1C, however, the antibody against TDP-
43 does not detect the transfected si-resistant proteins.
The most plausible explanation for this is that the eﬃ-
ciency of the siRNA transfection is greater than the add-
back eﬃciency. This has been conﬁrmed by western blot
experiments which show that the added-back protein
becomes visible using the anti-TDP-43 antibody only
after prolonged exposure of the autoradiographic ﬁlm
(data not shown). Although both the minigene and
the Flag-expressing plasmid are presumably transfected
together this diﬀerence in expression can also explain
why recovery of the ‘baseline’ inhibitory activity by TDP
WT and TBPH is not complete.
Testing the importance of hnRNP A/B proteins in CFTR
exon 9 splicing
In previous studies, using in vitro splicing assays, we
demonstrated that the ability of TDP-43 to repress a
UG-containing substrate, closely correlated with the abil-
ity of its C-terminal tail to bind several hnRNP proteins
(20). Currently, the only experimental evidence available
on the impact of hnRNP A/B proteins in CFTR splicing
in vivo is the observation from our lab that overexpression
of hnRNP A1 can downregulate its inclusion (35). We
have therefore performed a more extensive analysis of
the functional implicatons of hnRNP A/B protein levels
on CFTR exon 9 recognition through the knockdown
of hnRNP A1/A2 and C, either alone or in combination.
The results of this analysis are reported in Figure 2A.
This ﬁgure shows that knocking down both hnRNP A1
and A2, but not hnRNP C, results in considerable
increased levels of CFTR exon 9 inclusion with respect
to normal inclusion levels, as detected using our minigene
construct. Taken together, these results demonstrate that
hnRNP A/B proteins are powerful negative modulators of
CFTR exon 9 splicing. It could be argued, however, that
hnRNP A/B proteins exert their action through their bind-
ing to other RNA sequence elements in our minigene.
Therefore, to rule out this possibility, we have also per-
formed overexpression studies using hnRNP A1 and A2
on the CFTR 155T reporter minigene and a minigene
which carried a deletion of the TG sequence (TG) and
was thus unable to bind TDP-43. The results show that
overexpression of A1 and A2 in a TDP-43-dependent
CFTR context can successfully inhibit exon 9 recognition
(Figure 2B). On the other hand, this eﬀect cannot be
observed in a TDP-43 independent context (Figure 2C).
It should also noted that none of the hnRNP proteins
tested can bind UG repeats in a band-shift, ruling out
the possibility that hnRNP inhibitory action is mediated
by direct binding to the UG tract (20). An additional con-
sideration in this regard can also be made by the fact
that CFTR exon 9 inclusion is almost complete following
endogenous TDP-43 knockdown using siRNA (Figure 1).
This observation argues against an independent role of
hnRNP A1/A2 in CFTR exon 9 repression as this would
have been unaﬀected by just the removal of TDP-43.
Finally, Figure 2D shows that hnRNP A1 and A2 over-
expression in the absence of endogenous TDP-43 have
some minor independent activity on inhibiting exon inclu-
sion ( 10%), a phenomena that is found in a rather non-
speciﬁc fashion in many exons whenever hnRNP A1 or A2
are overexpressed (36). This could be due to low-aﬃnity
RNA binding sequences for A1 and A2 to the CFTR
RNA or to generalized protein–protein interactions.
Mapping the hnRNPA2–TDP-43 interaction using
truncation and deletion mutants
To map the hnRNP binding region more precisely, we
progressively shortened the TDP-43 C-terminus at resi-
dues 315 and 366, respectively (Figure 3A). The resulting
mutants were then assayed both in our splicing system and
in an in vitro super-shift binding assay with recombinant
hnRNP A2. As shown in Figure 2B, the add-back of TDP-
43 lacking the last 51 residues of the C-terminus (mutant
1-366) resulted in a recovery of inhibition (Figure 3B,
Figure 2. (A) The eﬀect of siRNA knockdown of hnRNP A1, A2 and
C on CFTR exon 9 splicing (either singly or in combination). The level
of knockdown of each of these hnRNP proteins was assayed by western
blot and is reported in the lower panels. The eﬀects of overexpressing
the hnRNP A1 and A2 proteins (either alone or in combination) in the
presence of TG11T5- and TG-containing CFTR minigenes are shown
in (B) and (C), respectively. (D) The eﬀect of overexpressing hnRNP
A1, A2 and si-resistant TDP-43 on a CFTR UG11U5 background
in the absence of endogenous TDP-43. Standard deviations obtained
in three independent transfection experiments are shown for Figure S1B
and S1D.
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(Figure 3B, lane 3). On the other hand, further shortening
of the C-terminus, down to residue 315, resulted in a sub-
stantial reduction of inhibitory activity (Figure 3B, lane
5). Consistently, shortening of the C-terminus to residue
315 also decreased the ability to bind hnRNP A2 as seen
by the lack of a super-shifted top band in EMSA
(Figure 3C). Taken together, these results suggest that
removing residues 366-414 has no eﬀect both on A/B pro-
tein binding and splicing inhibition whilst removing resi-
dues 315-414 can abrogate both functional properties.
Therefore, as a further control we removed the region
between amino acid residues 321 and 366 (321-366)
(Figure 4A) and assayed this mutant for both minigene
splicing and hnRNP A2 binding in EMSA analysis. As
additional control for the minigene experiment, we used
a previously described mutant that lacks the entire C-ter-
minus region (C) and is unable to restore CFTR exon 9
inhibition in an in vitro splicing system (19). The results
obtained in the analyses with the 321-366 mutant are
reported in Figure 4B and C. While the lack of interaction
of 321-366 TDP-43 with hnRNP A2 is a clear and
deﬁnitive result (Figure 4B), the recovery of splicing inhi-
bition is not as clear as observed with the C protein
(compare inhibition levels of Figure 4B, lanes 4 and 5).
Furthermore, when we tried to narrow down this region
even further by introducing smaller deletions (residues 321
to 346 and 346 to 366, for a schematic diagram see
Figure S1A) both mutants were able to inhibit CFTR
exon 9 inclusion in add-back assays, like the WT TDP-
43 molecule (Figure S1B). These results suggest that,
although the 321-366 region represents the minimal
region required for binding hnRNP A2 and is important
for splicing inhibition functionality, the total splicing inhi-
bition eﬀect of TDP-43 is not conﬁned to just this speciﬁc
punctual sequence but may be a function of a slightly
wider region of the C-terminus.
A synthetic peptide spanning residues 321-366 can disrupt
the TDP-43–hnRNP A2 interaction
In order to further establish whether residues 321-366
were the only requirement for interaction with hnRNP
A2, a peptide containing these residues was synthesized
(p321-366). This reagent was then used in a super-shift
assay to test whether it was capable of competing the
TDP-43–hnRNP A2 interaction. The results of this ana-
lysis are reported in Figure 5. They show that increasing
concentrations up to a 240-fold molar excess of p321-366
can eﬃciently compete for the interaction between TDP-
43 and hnRNP A2. A control peptide, pcont, added in
equal amounts, had no eﬀect on the TDP-43–hnRNP
A2 interaction. Finally, in keeping with the results
obtained in Figure S1B, the two peptides containing
the smaller 321-346 and 346-366 deletions were unable
to compete for hnRNPA2 binding to TDP-43 WT
(Figure S1, panel C).
Figure 3. (A) A diagram of WT TDP-43 and of two mutants truncated at residues 315 and 366, respectively. The RT–PCRs in (B) show the splicing
inhibitory activity of TDP-43 1-366 and 1-315 with respect to TDP WT. Standard deviations obtained in three independent transfection experiments
are shown. Western blots against the TDP-43, tubulin and FLAG peptide are shown below to show silencing eﬃciency, equal expression and proper
transgene expression. (C) An EMSA super-shift analysis of the binding between the WT TDP-43, 1-366 and 1-315 TDP-43 mutants with hnRNP A2.
Super-shifted complexes are indicated by an arrow.
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C-terminus region
Interestingly, some of the familial and sporadic ALS
patients bear mutations in TDP-43 and practically all
with just one exception reside in the C-terminus (30). In
particular, three mutations have been described to occur
in the 321-366 region where we mapped the hnRNPA2
interaction: Q331K (22), M337V (22) and G348C (23)
(Figure 6A). This observation raised the possibility that
some of these mutations might interfere with hnRNP
binding to TDP-43 and thus disrupt its splicing function.
However, as shown in Figure 6B and C none of the
mutants was able to disrupt either binding to hnRNP
A2 in the EMSA assay or the splicing inhibitory activity
on the CFTR exon minigene. Collectively, these results
suggest that the eﬀect of these mutants does not interfere
with the RNA splicing function of TDP-43. We further
investigated the eﬀects of Q331K, M337V and G348C on
their potential ability to disrupt the interactions with addi-
tional hnRNPs (A1, C, B1, A3), previously described for
WT TDP-43 protein (20). The GST-overlay assays, shown
in Figure 7, demonstrate that the entire cluster of hnRNP
proteins recognized by TDP-43 is conserved for the
mutants carrying the Q331K, M337V and G348C dis-
ease-related substitutions. The quantitative diﬀerences
observed in the diﬀerent samples are due to the fact that
all ﬁlters have been developed using the ECL detection
Figure 4. (A) A schematic diagram of the TDP-43 mutants lacking residues 321-366 and the entire C-terminal sequence from residue 216 (C).
(B) The splicing inhibitory activity of these two mutants compared to TDP-43 WT. The standard deviations obtained in three independent
transfection experiments are reported. Western blots against the TDP-43, tubulin and FLAG peptide are shown below to show silencing eﬃciency,
equal expression and proper transgene expression. (C) An EMSA analysis of the binding between TDP-43 WT, the 321-366 truncation mutant
(321-366) and hnRNP A2. Super-shifted complexes are indicated by an arrow.
Figure 5. Super-shift EMSA analysis of the binding between TDP-43
WT and hnRNP A2 in the presence of increasing quantities of a
peptide (0.5, 1 and 2mg, respectively, to obtain 60/120/240 molar
excess, respectively) spanning residues 321-366 of TDP-43 (p321-366).
Equal quantities of a control peptide (pcont) were used as control.
Super-shifted complexes are indicated by an arrow.
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do not necessarily reﬂect a diﬀerence in binding aﬃnity
as it is very diﬃcult to set up a quantitative GST-overlay
assay when comparing diﬀerent proteins obtained from
diﬀerent expression batches. What this experiment shows
is that no new interactions have been created by the muta-
tions introduced in the protein sequence and that all pre-
vious hnRNP interactions have been maintained within
experimental limitations.
Comparing the sequence similarities and hnRNP binding
abilities of TBPH and TDP-43
The alignment in Figure 8A shows the amino acid homol-
ogy between the human TDP-43 C-terminal region and
that of its homologous found in species from diﬀerent
phyla: marsupials (Opossum, Monodelphis domestica),
birds (Chicken, Gallus gallus), amphibians (Frog,
Xenopus laevis) and ﬁsh (Zebraﬁsh, Danio rerio). This
alignment indicates that the C-terminus is particularly
conserved in the region between residues 321 and 350,
suggesting that the ability of TDP-43 to bind hnRNP
A2 may also be highly conserved as well. Intriguingly,
however, the comparison between the sequences of
TBPH and human TDP-43 sequences (Figure 8B) shows
that the two proteins are highly similar in the N-terminal
and the RRM-containing regions but are considerably
divergent in the C-terminal tail (both with regards to the
length and primary sequence). However, in Figure 1C we
show that add-back of TBPH has the same inhibitory
eﬀects of TDP-43, a result that is consistent with previous
experiments showing that the in vitro inhibitory ability of
TBPH is comparable to that of TDP-43. The ability to
block exon recognition by TBPH requires the presence
of its C-terminal tail (19). We therefore wanted to see
Figure 6. (A) The location of the disease associated missense substitutions found in ALS patients (Q331K, M337V and G348C). Their eﬀect on the
ability to bind hnRNP A2 in an EMSA super-shift analysis with hnRNP A2 (indicated by an arrow) and to inhibit splicing compared to TDP-43 WT
are reported in (B) and (C), respectively. For the transfection experiments, standard deviations obtained in three independent experiments are shown.
Western blots against the TDP-43, tubulin and FLAG peptide are shown below to show silencing eﬃciency, equal expression and proper transgene
expression.
Figure 7. The left panel shows the Ponceau protein proﬁle of HeLa cell
nuclear extract (NE) and cytoplasmic extract (S100) run on a standard
10% SDS–PAGE gel. Molecular weights (kDa) are shown on the left.
The remaining panels show the result of GST-overlay assays performed
on a western blot containing the same amount of NE and S100 protein
using TDP-43 WT and with TDP-43 carrying the following mutations:
Q331K, M337V and G348C. Nuclear and cytoplasmic proteins specif-
ically recognized by the GST-recombinant protein were revealed by
ECL following incubation with an anti-GST antibody. The hnRNP
cluster recognized by these proteins is indicated.
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binding to human hnRNP A2. The results in Figure 8C
show that recombinant hnRNP A2 could eﬃciently bind
to TBPH and that binding was abolished upon deletion of
the C-terminal tail (TBPH C mutant). In order to deﬁ-
nitively conﬁrm this, we have performed the same compe-
tition experiment described in Figure 5 using the 321-366
peptide as a competitor for TBPH-hnRNP A2 binding.
The results shown in Figure 8D establish that the
human 321-366 residues can be an eﬀective competitor
for this interaction. These results are consistent with the
add-back assays reported in Figure 1 and suggest that
hnRNP binding is conserved in the Drosophila homolog
despite limited amino acid conservation. To address
whether the ability to bind the other members of the
hnRNP family (20), in addition to hnRNP A2, is con-
served in the case of TBPH we performed a GST-overlay
experiment using TBPH and TBPH C (as control).
Figure 9 shows that the cluster of hnRNP proteins recog-
nized by TDP-43 is also basically conserved for TBPH.
Moreover, it shows that recognition of all these proteins
is also completely abolished after the removal of the
C-terminal tail (TBPH C mutant).
DISCUSSION
TDP-43 is a member of the hnRNP protein family and its
414 amino acid sequence consists of an N-terminal region,
two RRM domains and a C-terminal region. Like many
members of this family, the C-terminal region contains
Figure 8. The alignment in (A) shows the sequence homology between the human TDP-43 C-terminal region (hu) and its homologous sequences in
Op, Opossum (Monodelphis domestica); Ch, Chicken (Gallus gallus); Fr, Frog (Xenopus laevis); and Ze, Zebraﬁsh (Danio rerio). The 321-366 region is
highlighted in bold. (B) The alignment between the full length human TDP-43 and full length Drosophila TBPH. The conserved RRM1 and RRM2
regions are highlighted in bold. (C) An EMSA super-shift analysis with hnRNP A2 of the binding between full length TBPH and a C-terminal
truncated TBPH mutant (TBPH C). Super-shifted complexes are indicated by an arrow. (D) A super-shift EMSA analysis of the binding between
TBPH and hnRNP A2 in the presence of increasing quantities of the 321-366 TDP-43 peptide (p321-366) and of a control peptide (pcont) in the
same quantities described for Figure 5. Super-shifted complexes are indicated by arrows.
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factors that can modulate TDP-43 function. Currently, the
only protein factors whose association to TDP-43 has
been veriﬁed are several members of the hnRNP family
(20) and the survival of motor neuron (SMN) protein (37).
The C-terminal tail does not seem to play a role in the
interaction with SMN. Other additional factors have also
been suggested to interact with this protein on the basis of
protein–protein association studies that use high-through-
put methodologies (38). In particular, two proteomics stu-
dies (39,40) involving yeast two hybrid systems found
some other potential TDP-43 binding partners, namely
XRN2 and PM/Scl100, involved in mRNA decay,
ZHX1, a transcriptional repressor, SETDB1, a chromatin
remodeling regulator, and NSFL1C and ARF6, both
involved in membrane traﬃcking. In this respect, it is
important to note that TDP-43 has been described to be
part of RNA granules responsible for traﬃcking, seques-
tering and degrading RNA species (41) and has been
observed to colocalize strongly with Staufen, moderately
with TIA-1 and weakly with XRN1, an exoribonuclease
involved in mRNA decay (42). Finally, TDP-43 has also
been found associated with both human and mouse micro-
processor complexes (43,44), suggesting that it may also
be involved in the biosynthesis of microRNAs. However,
many of these interactions are diﬃcult to interpret in
terms of the functional role of the complexes due to the
lack of more stringent biochemical evidence. In this work,
we have presented a new siRNA/minigene coupled system
to assess the in vivo splicing inhibitory activity of TDP-43
mutants and homolog proteins. Our results have fully con-
ﬁrmed previous in vitro data regarding the functional
interaction of TDP-43 with hnRNP proteins. In particu-
lar, we have focused on hnRNP A2, the major hnRNP
protein recognized by TDP-43 according to pull-down
assays (19,20). We have now identiﬁed residues 321 to
366 of the TDP-43 C-terminal tail as the minimal binding
region required to bind hnRNP A2. In addition, we also
ﬁnd that this region is necessary for TDP-43 splicing
inhibitory activity in our in vivo system. Taken together,
these experiments strongly support the requirement for
TDP-43 to form an hnRNP complex through its C-termi-
nus to inhibit exon splicing. Interestingly, the size of the
321-366 region (although not its sequence) is strikingly
similar to the 39 amino acid-long M9 regions described
in the hnRNP A/B proteins that enables the bidirectional
transport of these proteins across the nuclear envelope
through binding to transportin, also known as Kapb2
(45,46). It has been recently shown that the M9 region
of hnRNP A1 protein binds a concave surface of a
C-terminal arch in Kapb2 in an extended conformation
(residues 263 to 289 of this protein) making an extensive
network of polar and hydrophobic contacts (45). A similar
situation may occur in the TDP-43–hnRNPA2 interaction
and could explain the fact that three missense mutations in
the 321-366 region associated with neurodegeneration do
not substantially aﬀect binding eﬃciency and splicing
function. Altogether, these data suggest that the muta-
tions in TDP-43 found in patients do not contribute to a
drastic protein loss of function. More likely, they may
contribute to a predisposition to develop the disease (i.e.
more readily form aggregates) through some still uniden-
tiﬁed mechanisms. Given the late age of onset of both
ALS and FTLD, another possibility is that the mutations
aﬀect TDP-43 function to a small degree (not detectable
in our assays), but the slight disruption of its activity per-
petuated over a long time might be the cause for the neu-
rodegeneration. The same concept has been proposed to
be the cause of neurodegeneration in Spinal Muscular
Atrophy patients with a slight decrease in SMN protein
(47,48). Further work is currently in progress to better
deﬁne the TDP-43–hnRNP A2 interaction through the
identiﬁcation of the hnRNP A2 residues involved. The
TDP-43 interacting domain should be localized in the
C-terminal tail of hnRNP A2 as previously reported
(20). These experiments will provide a better indication
of the TDP-43 residues involved in the interaction and
thus in a better position to judge the eﬀect of eventual
disease causing mutations.
From a functional point of view, characterization of the
TDP-43–hnRNP interaction is essential to understand its
splicing regulatory properties, especially in light of recent
observations regarding the potential existence of human
alternatively spliced variants that lack the C-terminal tail
(49,50). Although at the moment there is scant biochem-
ical evidence regarding the relative abundance or distribu-
tion pattern of these isoforms in humans, it is clear that
their existence and or production would carry distinct bio-
logical properties with respect to the WT protein but
would still be able to compete for the same binding sites
(UG repeats). Therefore, in addition to variations in the
relative hnRNP A/B proteins present in diﬀerent tissues
or developmental stages, expression of these truncated
isoforms may also prove to be a good way to modulate
Figure 9. The left panel shows the Ponceau protein proﬁle of HeLa cell
nuclear extract (NE) and cytoplasmic extract (S100) run on a standard
10% SDS–PAGE gel. Molecular weights (kDa) are shown on the left.
The remaining panels show the result of three GST-overlay assays
using the following proteins: human TDP-43 WT, Drosophila TBPH
and Drosophila TBPH C as a control. Nuclear and cytoplasmic pro-
teins speciﬁcally recognized by the GST-recombinant protein were
revealed by ECL following incubation with an anti-GST antibody.
The hnRNP cluster recognized by these proteins is indicated.
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More in general, our results represent a clear indication
that interactions between splicing regulatory proteins
belonging to distinct classes can be a powerful modiﬁer
of their functional properties. In fact, it was well known
that functional biochemical interactions between hnRNPs
of the same type can explain their eﬀect on splicing. For
example, it has been proposed that a variety of proteins,
such as PTB, hnRNP H and hnRNP A/B can potentially
multimerize to create ‘zones of silencing’ across exons or
modulate the conformation of the pre-mRNA and thereby
inﬂuence exon recognition (51–54). Less often, protein
networking has been described to occur between diﬀerent
factors. One such interaction has been described for the
PTB–Raver1 interaction in the control of the tropomyosin
gene (55,56), a case where both proteins can synergistically
repress exon recognition. More recently, the presence of a
functionally relevant biochemical interaction between the
hnRNP H/F proteins and Fox2 has been reported (57).
In this case, the interaction between hnRNP H and Fox2
is capable of altering the binding ability of the complex
and thereby to inﬂuence the splicing inhibitory eﬀect of
the H/F proteins on FGFR2 exon IIIc.
Finally, all these observations of intricate biochemical
connections between splicing factors of diﬀerent classes
will certainly add a layer of complexity to the well-estab-
lished concept of combinatorial and context-dependent
control in splicing (58–60). In order to understand splicing
outcomes in the future, it will not be enough to simply
identify all the trans-acting factors that bind to the RNA
sequence in the vicinity of an exon. More probably, it will
also be necessary to consider the relative expression
levels and regulation of cellular factors that do not directly
contact the RNA under study, but which can modify the
functional properties of the factors that do.
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